Article

Cellares and the University of Wisconsin School of Medicine and Public Health have expanded their partnership to support clinical manufacturing of the CRISPR-edited GD2 CAR-T therapy for solid tumors. This collaboration builds on a previous partnership established in April 2025.

Cellares will utilize its Cell Shuttle™ and Cell Q™ platforms to provide automated manufacturing and regulatory support for the Investigational New Drug (IND) application to the FDA. The GD2 CAR-T program targets high-grade gliomas and may extend to other GD2+ cancers. The automation aims to reduce manual handling and variability, facilitating the transition from development to clinical trials.